Teachers Advisors’s Kite Pharma, Inc. KITE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-128,241
| Closed | -$23.1M | – | 3118 |
|
|
2017
Q3 | $23.1M | Sell |
128,241
-4,968
| -4% | -$692K | 0.03% | 609 |
|
|
2017
Q2 | $13.8M | Buy |
133,209
+13,460
| +11% | +$1.1M | 0.02% | 843 |
|
|
2017
Q1 | $9.4M | Buy |
119,749
+3,014
| +3% | +$186K | 0.01% | 1016 |
|
|
2016
Q4 | $5.23M | Buy |
116,735
+2,537
| +2% | +$124K | 0.01% | 1256 |
|
|
2016
Q3 | $6.38M | Buy |
114,198
+14,348
| +14% | +$799K | 0.01% | 1115 |
|
|
2016
Q2 | $4.99M | Buy |
99,850
+13,499
| +16% | +$663K | 0.01% | 1175 |
|
|
2016
Q1 | $3.96M | Buy |
86,351
+5,946
| +7% | +$288K | 0.01% | 1232 |
|
|
2015
Q4 | $4.96M | Buy |
80,405
+22,600
| +39% | +$1.59M | 0.01% | 1142 |
|
|
2015
Q3 | $3.22M | Buy |
57,805
+14,237
| +33% | +$896K | 0.01% | 1309 |
|
|
2015
Q2 | $2.66M | Buy |
43,568
+30,415
| +231% | +$1.74M | ﹤0.01% | 1505 |
|
|
2015
Q1 | $759K | Buy |
13,153
+1,537
| +13% | +$103K | ﹤0.01% | 2204 |
|
|
2014
Q4 | $670K | Buy |
11,616
+3,576
| +44% | +$151K | ﹤0.01% | 2264 |
|
|
2014
Q3 | $229K | Buy |
+8,040
| New | +$199K | ﹤0.01% | 2821 |
|
Teachers Advisors's KITE Position: Q4 2017 in Review
Teachers Advisors sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 128,241 shares — an estimated $23.1M sold.
Teachers Advisors first reported a position in KITE in Q3 2014 and held it in 13 quarters. The position peaked at $23.1M in Q3 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.
- Teachers Advisors reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
- Teachers Advisors sold 128,241 Kite Pharma, Inc. shares in Q4 2017, an estimated $23.1M.
- Teachers Advisors first reported a position in Kite Pharma, Inc. in Q3 2014 and held it in 13 quarters.
- Teachers Advisors's Kite Pharma, Inc. position peaked at $23.1M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.
Based on Teachers Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.